Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Targeting PDZ binding kinase is anti-tumorigenic in novel preclinical models of ACC.

Kar A, Zhang Y, Yacob B, Saeed JM, Tompkins KD, Bagby S, Pitts TM, Somerset HL, Leong S, Wierman M, Kiseljak-Vassiliades K.

Endocr Relat Cancer. 2019 Jul 1. pii: ERC-19-0262. doi: 10.1530/ERC-19-0262. [Epub ahead of print]

PMID:
31325906
2.

How Genomics Is Changing What We Know About the Evolution and Genome of Bordetella pertussis.

Ring N, Abrahams JS, Bagby S, Preston A, MacArthur I.

Adv Exp Med Biol. 2019 Jul 19. doi: 10.1007/5584_2019_401. [Epub ahead of print]

PMID:
31321755
3.

Chronic Kidney Disease: A Life Course Health Development Perspective.

Brophy PD, Charlton JR, Bryan Carmody J, Reidy KJ, Harshman L, Segar J, Askenazi D, Shoham D, Bagby SP.

In: Halfon N, Forrest CB, Lerner RM, Faustman EM, editors. Handbook of Life Course Health Development [Internet]. Cham (CH): Springer; 2018.
2017 Nov 21.

4.

Altered vertebral and femoral bone structure in juvenile offspring of microswine subject to maternal low protein nutritional challenge.

Lanham SA, DuPriest E, Kupfer P, Cooper C, Bagby SP, Oreffo ROC.

Physiol Rep. 2019 Jun;7(11):e14081. doi: 10.14814/phy2.14081.

5.

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.

Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG.

J Immunother Cancer. 2019 Feb 8;7(1):37. doi: 10.1186/s40425-019-0518-z.

6.

From the Outside In: Biological Mechanisms Linking Social and Environmental Exposures to Chronic Disease and to Health Disparities.

Bagby SP, Martin D, Chung ST, Rajapakse N.

Am J Public Health. 2019 Jan;109(S1):S56-S63. doi: 10.2105/AJPH.2018.304864.

7.

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.

Schreiber AR, Nguyen A, Bagby SM, Arcaroli JJ, Yacob BW, Quackenbush K, Guy JL, Crowell T, Stringer B, Danaee H, Kalebic T, Messersmith WA, Pitts TM.

Clin Cancer Drugs. 2018;5(1):42-49. doi: 10.2174/2212697X05666180516120907.

8.

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.

Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Kami R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.

Mol Cancer Ther. 2019 Feb;18(2):278-288. doi: 10.1158/1535-7163.MCT-18-0456. Epub 2018 Nov 27.

PMID:
30482852
9.

Resolving the complex Bordetella pertussis genome using barcoded nanopore sequencing.

Ring N, Abrahams JS, Jain M, Olsen H, Preston A, Bagby S.

Microb Genom. 2018 Nov;4(11). doi: 10.1099/mgen.0.000234. Epub 2018 Nov 21.

10.

CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.

Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, Robinson WA, Messersmith WA, Fujita M.

Cancer Res. 2018 Dec 1;78(23):6561-6574. doi: 10.1158/0008-5472.CAN-18-0330. Epub 2018 Oct 8.

PMID:
30297536
11.

BRAF fusions identified in melanomas have variable treatment responses and phenotypes.

Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL.

Oncogene. 2019 Feb;38(8):1296-1308. doi: 10.1038/s41388-018-0514-7. Epub 2018 Sep 25.

PMID:
30254212
12.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.

Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S.

Anticancer Drugs. 2018 Oct;29(9):827-838. doi: 10.1097/CAD.0000000000000673.

13.

Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.

Scott AJ, Arcaroli JJ, Bagby SM, Yahn R, Huber KM, Serkova NJ, Nguyen A, Kim J, Thorburn A, Vogel J, Quackenbush KS, Capasso A, Schreiber A, Blatchford P, Klauck PJ, Pitts TM, Eckhardt SG, Messersmith WA.

Mol Cancer Ther. 2018 Oct;17(10):2112-2122. doi: 10.1158/1535-7163.MCT-17-0131. Epub 2018 Jul 19.

PMID:
30026382
14.

Effects of postweaning calorie restriction on accelerated growth and adiponectin in nutritionally programmed microswine offspring.

DuPriest EA, Lin B, Kupfer P, Sekiguchi K, Bhusari A, Quackenbush A, Celebic A, Morgan TK, Purnell JQ, Bagby SP.

Am J Physiol Regul Integr Comp Physiol. 2018 Aug 1;315(2):R354-R368. doi: 10.1152/ajpregu.00162.2017. Epub 2018 Jun 20.

PMID:
29924631
15.

Distinctive phosphoinositide- and Ca2+-binding properties of normal and cognitive performance-linked variant forms of KIBRA C2 domain.

Posner MG, Upadhyay A, Ishima R, Kalli AC, Harris G, Kremerskothen J, Sansom MSP, Crennell SJ, Bagby S.

J Biol Chem. 2018 Jun 15;293(24):9335-9344. doi: 10.1074/jbc.RA118.002279. Epub 2018 May 3.

16.

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM.

BMC Cancer. 2018 Feb 5;18(1):136. doi: 10.1186/s12885-018-4036-z.

17.

Development of new preclinical models to advance adrenocortical carcinoma research.

Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME.

Endocr Relat Cancer. 2018 Apr;25(4):437-451. doi: 10.1530/ERC-17-0447. Epub 2018 Jan 25.

18.

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.

Greene J, Nguyen A, Bagby SM, Jones GN, Tai WM, Quackenbush KS, Schreiber A, Messersmith WA, Devaraj KM, Blatchford P, Eckhardt SG, Cadogan EB, Hughes GD, Smith A, Pitts TM, Arcaroli JJ.

Oncotarget. 2017 Dec 5;8(67):110904-110913. doi: 10.18632/oncotarget.22920. eCollection 2017 Dec 19.

19.

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.

Scott AJ, Song EK, Bagby S, Purkey A, McCarter M, Gajdos C, Quackenbush KS, Cross B, Pitts TM, Tan AC, Eckhardt SG, Fenton H, Arcaroli J, Messersmith WA.

PLoS One. 2017 Nov 1;12(11):e0187173. doi: 10.1371/journal.pone.0187173. eCollection 2017.

20.

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA.

Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20.

21.

International summit on the nutrition of adolescent girls and young women: consensus statement.

Krebs N, Bagby S, Bhutta ZA, Dewey K, Fall C, Gregory F, Hay W Jr, Rhuman L, Caldwell CW, Thornburg KL.

Ann N Y Acad Sci. 2017 Jul;1400(1):3-7. doi: 10.1111/nyas.13417. Epub 2017 Jul 19.

22.

Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate Corynebacterium bovis.

Manuel CA, Bagby SM, Reisinger JA, Pugazhenthi U, Pitts TM, Keysar SB, Arcaroli JJ, Leszczynski JK.

J Am Assoc Lab Anim Sci. 2017 Mar 1;56(2):166-172.

23.

Methane-Oxidizing Bacteria Shunt Carbon to Microbial Mats at a Marine Hydrocarbon Seep.

Paul BG, Ding H, Bagby SC, Kellermann MY, Redmond MC, Andersen GL, Valentine DL.

Front Microbiol. 2017 Feb 27;8:186. doi: 10.3389/fmicb.2017.00186. eCollection 2017.

24.

Persistence and biodegradation of oil at the ocean floor following Deepwater Horizon.

Bagby SC, Reddy CM, Aeppli C, Fisher GB, Valentine DL.

Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E9-E18. doi: 10.1073/pnas.1610110114. Epub 2016 Dec 19.

25.

Kinase gene fusions in defined subsets of melanoma.

Turner J, Couts K, Sheren J, Saichaemchan S, Ariyawutyakorn W, Avolio I, Cabral E, Glogowska M, Amato C, Robinson S, Hintzsche J, Applegate A, Seelenfreund E, Gonzalez R, Wells K, Bagby S, Tentler J, Tan AC, Wisell J, Varella-Garcia M, Robinson W.

Pigment Cell Melanoma Res. 2017 Jan;30(1):53-62. doi: 10.1111/pcmr.12560.

26.

Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).

Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG.

Invest New Drugs. 2017 Feb;35(1):11-25. doi: 10.1007/s10637-016-0398-8. Epub 2016 Oct 25.

27.

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.

Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J.

J Vis Exp. 2016 Sep 30;(115). doi: 10.3791/54393.

28.

A Modular Bioplatform Based on a Versatile Supramolecular Multienzyme Complex Directly Attached to Graphene.

Alshammari A, Posner MG, Upadhyay A, Marken F, Bagby S, Ilie A.

ACS Appl Mater Interfaces. 2016 Aug 17;8(32):21077-88. doi: 10.1021/acsami.6b05453. Epub 2016 Aug 5.

PMID:
27447357
29.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

30.

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.

Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, Kim J, Wang G, Purkey A, Pitts TM, Nguyen A, Gao D, Blatchford P, Capasso A, Schuller AG, Eckhardt SG, Arcaroli JJ.

Oncotarget. 2016 May 10;7(19):28273-85. doi: 10.18632/oncotarget.8626.

31.

Topoisomerase IIα mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.

Zhou Q, Abraham AD, Li L, Babalmorad A, Bagby S, Arcaroli JJ, Hansen RJ, Valeriote FA, Gustafson DL, Schaack J, Messersmith WA, LaBarbera DV.

Oncogene. 2016 Sep 22;35(38):4990-9. doi: 10.1038/onc.2016.29. Epub 2016 Mar 7.

32.

Extracellular Fibrinogen-binding Protein (Efb) from Staphylococcus aureus Inhibits the Formation of Platelet-Leukocyte Complexes.

Posner MG, Upadhyay A, Abubaker AA, Fortunato TM, Vara D, Canobbio I, Bagby S, Pula G.

J Biol Chem. 2016 Feb 5;291(6):2764-76. doi: 10.1074/jbc.M115.678359. Epub 2015 Dec 1.

33.

Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma.

Singh S, Arcaroli JJ, Orlicky DJ, Chen Y, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Thompson DC, Vasiliou V.

Pancreas. 2016 Jan;45(1):117-22. doi: 10.1097/MPA.0000000000000542.

34.

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.

Oncotarget. 2015 Oct 27;6(33):34561-72. doi: 10.18632/oncotarget.5949.

35.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA.

Int J Cancer. 2016 Jan 1;138(1):195-205. doi: 10.1002/ijc.29676. Epub 2015 Jul 22.

36.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG.

Front Pharmacol. 2015 Jun 16;6:120. doi: 10.3389/fphar.2015.00120. eCollection 2015.

37.

Response of Prochlorococcus to varying CO2:O2 ratios.

Bagby SC, Chisholm SW.

ISME J. 2015 Oct;9(10):2232-45. doi: 10.1038/ismej.2015.36. Epub 2015 Apr 7.

38.

Targeted diversity generation by intraterrestrial archaea and archaeal viruses.

Paul BG, Bagby SC, Czornyj E, Arambula D, Handa S, Sczyrba A, Ghosh P, Miller JF, Valentine DL.

Nat Commun. 2015 Mar 23;6:6585. doi: 10.1038/ncomms7585.

39.

YAP is essential for tissue tension to ensure vertebrate 3D body shape.

Porazinski S, Wang H, Asaoka Y, Behrndt M, Miyamoto T, Morita H, Hata S, Sasaki T, Krens SFG, Osada Y, Asaka S, Momoi A, Linton S, Miesfeld JB, Link BA, Senga T, Shimizu N, Nagase H, Matsuura S, Bagby S, Kondoh H, Nishina H, Heisenberg CP, Furutani-Seiki M.

Nature. 2015 May 14;521(7551):217-221. doi: 10.1038/nature14215. Epub 2015 Mar 16.

40.

Transient expression in HEK 293 cells: an alternative to E. coli for the production of secreted and intracellular mammalian proteins.

Nettleship JE, Watson PJ, Rahman-Huq N, Fairall L, Posner MG, Upadhyay A, Reddivari Y, Chamberlain JM, Kolstoe SE, Bagby S, Schwabe JW, Owens RJ.

Methods Mol Biol. 2015;1258:209-22. doi: 10.1007/978-1-4939-2205-5_11. Review.

PMID:
25447866
41.

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.

PLoS One. 2014 Nov 17;9(11):e113037. doi: 10.1371/journal.pone.0113037. eCollection 2014.

42.

Fallout plume of submerged oil from Deepwater Horizon.

Valentine DL, Fisher GB, Bagby SC, Nelson RK, Reddy CM, Sylva SP, Woo MA.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15906-11. doi: 10.1073/pnas.1414873111. Epub 2014 Oct 27.

43.

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ.

Int J Cancer. 2015 Apr 15;136(8):1967-75. doi: 10.1002/ijc.29225. Epub 2014 Sep 29.

44.

Comparative genomic analysis reveals 2-oxoacid dehydrogenase complex lipoylation correlation with aerobiosis in archaea.

Borziak K, Posner MG, Upadhyay A, Danson MJ, Bagby S, Dorus S.

PLoS One. 2014 Jan 28;9(1):e87063. doi: 10.1371/journal.pone.0087063. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e100680.

45.

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.

Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, Messersmith WA.

Br J Cancer. 2013 Aug 6;109(3):667-75. doi: 10.1038/bjc.2013.361. Epub 2013 Jul 18.

46.

Post-translational modification in the archaea: structural characterization of multi-enzyme complex lipoylation.

Posner MG, Upadhyay A, Crennell SJ, Watson AJ, Dorus S, Danson MJ, Bagby S.

Biochem J. 2013 Jan 15;449(2):415-25. doi: 10.1042/BJ20121150.

PMID:
23116157
47.

The Hippo pathway: key interaction and catalytic domains in organ growth control, stem cell self-renewal and tissue regeneration.

Cherrett C, Furutani-Seiki M, Bagby S.

Essays Biochem. 2012;53:111-27. doi: 10.1042/bse0530111. Review.

PMID:
22928512
48.

Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.

Belcik JT, Qi Y, Kaufmann BA, Xie A, Bullens S, Morgan TK, Bagby SP, Kolumam G, Kowalski J, Oyer JA, Bunting S, Lindner JR.

J Am Coll Cardiol. 2012 Aug 14;60(7):618-25. doi: 10.1016/j.jacc.2012.02.053. Epub 2012 Jun 13.

49.

Altered adipocyte structure and function in nutritionally programmed microswine offspring.

DuPriest EA, Kupfer P, Lin B, Sekiguchi K, Morgan TK, Saunders KE, Chatkupt TT, Denisenko ON, Purnell JQ, Bagby SP.

J Dev Orig Health Dis. 2012 Jun;3(3):198-209. doi: 10.1017/S2040174412000232.

50.

Accelerated growth without prepubertal obesity in nutritionally programmed microswine offspring.

DuPriest EA, Kupfer P, Lin B, Sekiguchi K, Purnell JQ, Saunders KE, Chatkupt TT, Bagby SP.

J Dev Orig Health Dis. 2012 Apr;3(2):92-102. doi: 10.1017/S2040174412000037.

Supplemental Content

Support Center